MSCLF - Satellos Bioscience Inc.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.4223 |
| Open | 0.4223 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.4223 - 0.4223 |
| 52 Week Range | 0.0300 - 1.0000 |
| Volume | |
| Avg. Volume | 20,579 |
| Market Cap | 47.624M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
- Newsfile
Satellos Bioscience Announces Appointment of Chief Medical Officer
Dr. Alan K. Jacobs joins Satellos as CMO on June 7th, 2023 Toronto, Ontario--(Newsfile Corp. - June 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today the appointment of Alan K. Jacobs, MD as Chief Medical Officer (CMO) of the Company, effective June 7, 2023."Dr. Jacobs is an accomplished and experienced clinical development .
- Newsfile
Satellos Bioscience Announces Grant of Stock Options
Toronto, Ontario--(Newsfile Corp. - June 1, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that its board of directors (the "Board") has approved grants of stock options (the "Stock Options") pursuant to the terms of the Company's Stock Option Plan. A total of 5,732,797 Stock Options have been awarded to directors, officers,
- Newsfile
Satellos Bioscience Announces 2023 Q1 Financial Results and Operational Highlights
- $55 million equity financing closed- Resourced to advance lead drug candidate into clinical trialsToronto, Ontario--(Newsfile Corp. - May 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today its financial results and operational highlights ...
- Newsfile
Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.
Toronto, Ontario--(Newsfile Corp. - May 17, 2023) - Bloom Burton & Co. Inc. announces that, today, it and its affiliate acquired 1,453,070 common shares (Shares) and 6,636,734 compensation options (Compensation Options) of Satellos Bioscience Inc. (Corporation) in connection with a public offering of the Corporation by way of a short form prospectus dated May 9, 2023. Bloom Burton purchased the Shares at a price of $0.50 per Share for total consideration of $726,535 ...
- Newsfile
Satellos Bioscience Closes $55M Financing to Support Development of its Lead Drug Candidate for Duchenne Muscular Dystrophy
Toronto, Ontario--(Newsfile Corp. - May 17, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that it has closed an equity offering, issuing a total of 110 million equity securities for gross proceeds of $55 million (the "Offering"). The Offering included participation from funds managed by Avidity Partners, Qiming Venture Partn
- Newsfile
Satellos Bioscience Inc. Announces Filing of Final Short Form Prospectus for Proposed Offering of Common Shares
Toronto, Ontario--(Newsfile Corp. - May 10, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce today that it has filed its final short form prospectus (the "Prospectus") with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with the Company's previously announced
- Newsfile
Satellos Bioscience Inc. Announces Pricing of Public Offering
Toronto, Ontario--(Newsfile Corp. - April 19, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce the pricing and terms of its previously announced best efforts public offering of common shares of the Company ("Common Shares") (or pre-funded common share purchase warrants ("Pre-Funded Warrants" and, together with the Common
- Newsfile
Satellos Bioscience Inc. Announces Public Offering of Common Shares
Toronto, Ontario--(Newsfile Corp. - April 18, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has filed a preliminary short form prospectus (the "Preliminary Prospectus") with the securities regulatory authorities in the Provinces of British Columbia, Alberta and Ontario in connection with a best efforts offering of co
- Zacks Small Cap Research
MSCLF: Preclinical Proof-of-Concept Data for SAT-3153 Presented at MDA Conference…
By David Bautz, PhD OTC:MSCLF READ THE FULL MSCLF RESEARCH REPORT Business Update Preclinical Data for SAT-3153 Presented at MDA Conference On March 19, 2023, Satellos Bioscience Inc. (OTC:MSCLF) announced the presentation of preclinical proof-of-concept data for its lead development compound, SAT-3153, at the Muscular Dystrophy Association Clinical and Scientific Conference. The company had
- Newsfile
Satellos Bioscience Announces 2022 Year End Financial Results and Operational Highlights
Toronto, Ontario--(Newsfile Corp. - March 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today its financial results and operational highlights for the year ending December 31, 2022. All dollar amounts are expressed in Canadian currency unless otherwise noted."Satellos mad
- Newsfile
Satellos Bioscience Announces Closing of Previously Announced Non-Brokered Offering of $2.385 Million of Unsecured Non-Convertible Debentures
Toronto, Ontario--(Newsfile Corp. - March 29, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, today announced it has closed its previously announced non-brokered private placement offering of 10% unsecured non-convertible debenture units (the "Units") for gross proceeds of $2,385,000 (th
- Newsfile
Satellos Bioscience Announces Upsize of Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures to up to $2.385 Million
Toronto, Ontario--(Newsfile Corp. - March 22, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, previously announced on March 15, 2023 a proposed non-brokered private placement offering (the "Offering") of 10% unsecured non-convertible debenture units (the "Units") pursuant to which Satell
- Newsfile
Satellos Bioscience to Present at Annual MDA Clinical and Scientific Conference and Insights in Research Investor Summit
Ryan Mitchell, PhD and Director of Business Development at Satellos to highlight SAT-3153 and Satellos' novel muscle regeneration technology in two forums at this year's MDA Conference and Summit Toronto, Ontario--(Newsfile Corp. - March 17, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging
- Newsfile
Satellos Bioscience Announces Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures of up to $2.25 Million
Toronto, Ontario--(Newsfile Corp. - March 15, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, today announced a proposed non-brokered private placement offering of 10% unsecured non-convertible debenture units (the "Units") pursuant to which Satellos proposes to raise gross proceeds of u
- Newsfile
Satellos Bioscience Announces Further Preclinical Progress with SAT-3153 As a Potential Treatment for Duchenne Muscular Dystrophy
Toronto, Ontario--(Newsfile Corp. - March 10, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce additional results from further preclinical studies using the Company's lead drug candidate SAT-3153. The Company has designed SAT-3153 to be a selective inhibitor of a pr
- Zacks Small Cap Research
A Fireside Chat with Frank Gleeson, MBA - Co-founder, CEO, and Board Member of Satellos Bioscience
OTC:MSCLF Richard Hantke: Hello everyone. My name's Richard Hantke, I'm with Zacks Small-Cap research. I'm here with Frank Gleeson, who is the co-founder and CEO of Satellos Bioscience (OTC:MSCLF). Hi, Frank. Frank Gleeson: Hi, Richard. How are you doing? Richard Hantke: Good, very good. For those of you that are not aware, Zacks Small-Cap Research, we're a division of Zacks Investment Research,
- Zacks Small Cap Research
MSCLF: SAT-3153 Selected as Lead Development Candidate…
By David Bautz, PhD OTC:MSCLF READ THE FULL MSCLF RESEARCH REPORT Business Update SAT-3153 Selected as Lead Development Candidate On January 3, 2023, Satellos Bioscience Inc. (OTC:MSCLF) announced the designation of SAT-3153 as its lead development candidate. SAT-3153 is a protein kinase inhibitor that targets a particular protein in the Notch signaling pathway (codenamed “K9”). Following results
- Newsfile
Satellos Bioscience Announces Significant Increase in Muscle Size and Function in Duchenne Muscular Dystrophy Disease Model
- 40% increase in muscle size compared to control mice - 25% increase in muscle force, approaching levels seen in normal miceToronto, Ontario--(Newsfile Corp. - February 6, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce results from multiple preclinical studies in
- Newsfile
Satellos Bioscience Announces Development Candidate
- SAT-3153 Designated for pre-IND Studies - Toronto, Ontario--(Newsfile Corp. - January 3, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce that it has designated SAT-3153 for development towards an IND filing."We are thrilled to be in a position to move SAT-3153 ..
- Newsfile
Satellos Bioscience Announces Q3 2022 Financial Results and Operational Highlights
Toronto, Ontario--(Newsfile Corp. - November 23, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today its financial results and operational highlights for the quarter ending September 30, 2022. The Company's interim condensed consolidated financial statements for the quarter ended September 30, 2022, a
- Zacks Small Cap Research
MSCLF: Initiating Coverage of Satellos Biosciences; A Muscle Regeneration Company…
By David Bautz, PhD OTC:MSCLF READ THE FULL MSCLF RESEARCH REPORT We are initiating coverage of Satellos Biosciences Inc. (OTC:MSCLF) with a $0.70 valuation. Satellos is a biopharmaceutical company developing treatments for muscle diseases, including muscular dystrophies and muscle loss associated with chronic illness and aging. Satellos’ core technology is based on discoveries by its scientific
- Newsfile
Satellos Bioscience Announces Advancement of Compounds to Next Stage of Development
-Proof of concept studies to be completed by YE- Toronto, Ontario--(Newsfile Corp. - November 3, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce that it has created, prioritized and advanced novel small molecule drug candidates into further preclinical studies.The Company's compounds have been
- Newsfile
Satellos Bioscience Inc. to Present Preliminary Preclinical Proof of Concept Data for an Additional Rare Disease at World Muscle Society Meeting
- Advancements on the Company's evaluation of potential new disease indication Toronto, Ontario--(Newsfile Corp. - October 11, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today that Ryan Mitchell, PhD and Director of Business Development will present preliminary preclinical proof of concept d
